MLYS
8:00 AM
News Updates
Wed, May 27, 2026
1 updatesMon, May 18, 2026
1 updatesMLYS
4:05 PM
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Presentation / Abstract • Phase 3Oral presentation Sat, May 30, 2026, 5:15 PM CESTmineralystx.com
Wed, May 6, 2026
1 updatesTue, May 5, 2026
2 updatesWed, Apr 29, 2026
1 updatesTue, Mar 24, 2026
1 updatesMLYS
8:00 AM
Mon, Mar 16, 2026
1 updatesThu, Mar 12, 2026
1 updatesMon, Mar 9, 2026
2 updatesMLYS
4:30 PM
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Trial Results • Phase 2mineralystx.com
MLYS
8:00 AM